ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Myelin-oligodendrocyte glycoprotein (MOG) antibody-associated acute disseminated encephalomyelitis (ADEM) in an adult with dengue.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Persistent and Long-Term Infectivity of Dengue Virus in Mosquito Cells Revealed Reduced Replication in Vector Host and Human Endothelial Cells.Pathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue is the most worldwide arbovirus and uncommonly causes encephalitis or acute disseminated encephalomyelitis (ADEM). Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) has recently been recognized as a spectrum of monophasic or relapsing course demyelininating syndromes. We present the first case of MOGAD ADEM in an adult with dengue from Brazil. The patient was a 21-year-old man with no relevant medical or epidemiological history and a confirmed diagnosis of dengue with no warning signs after three days of classical clinical manifestations. In the next days, the patient had lower limb weakness, acute urinary retention, diplopia, sonolence, and mental confusion. MRI showed multiple cerebral and spinal cord lesions compatible with ADEM. CSF analysis demonstrated pleocytosis (135 WBC/μL) and elevated protein (155 mg/L). Dengue-IgM antibodies were positive in the CSF. Serum MOG-IgG cell-based immunofluorescence assay was positive with a titer >1:160. The patient received methylprednisolone for five days, showing progressive and unequivocal improvement of neurological manifestations and he was discharged with oral prednisone This report suggests an emerging association between dengue induced immune dysregulation and the development of MOGAD-associated ADEM. The presence of MOG antibodies should be considered in adults with dengue-related ADEM and timely syndromic management may determine favorable outcomes.
Indexed as
Identifiers
41060337What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.